International Trial Restores Hearing in Patients With Genetic Deafness Through Breakthrough OTOF Gene Therapy

Mass Eye and Ear researchers restore hearing in 90% of trial participants using a new OTOF gene therapy, with lasting results for up to 2.5 years.

By: AXL Media

Published: Apr 23, 2026, 8:59 AM EDT

Source: Information for this report was sourced from Mass Eye and Ear

A Paradigm Shift in Treating Inherited Sensory Loss

A global research collaboration has achieved a major milestone in regenerative medicine by restoring hearing to children and adults born with profound genetic deafness. The study, published on April 22, 2026, in the journal Nature, targeted a specific condition known as autosomal recessive deafness 9, or DFNB9. This condition is caused by mutations in the OTOF gene, which prevent the production of otoferlin, a protein essential for transmitting sound signals from the inner ear to the brain. According to corresponding author Zheng-Yi Chen, DPhil, of Mass Eye and Ear, the results represent a remarkable transition for patients moving from total silence to the ability to recognize speech and communicate.

The Mechanics of Viral Gene Delivery

The experimental treatment utilizes a neutralized adeno-associated virus (AAV) as a delivery vehicle to transport a functional copy of the human OTOF gene directly into the cochlea. Once the working gene is integrated into the hair cells of the inner ear, the body begins producing the missing otoferlin protein, effectively repairing the biological pathway required for hearing. Unlike prosthetic devices like cochlear implants, which bypass damaged areas to stimulate the auditory nerve electrically, this gene therapy seeks to restore the natural physiological function of the ear. The procedure involves a single, minimally invasive injection, which researchers have now validated across multiple hospital settings.

Long Term Efficacy and Safety Profile

This trial stands as the largest and longest follow-up study of its kind, monitoring 42 participants for up to 30 months. The findings confirmed a high safety profile with no serious treatment-related side effects recorded. Auditory brainstem response (ABR) measurements showed that most participants experienced a reduction in hearing loss thresholds from profound levels to mild or near-normal levels within weeks of the injection. Furthermore, the improvements were not fleeting; the researchers documented sustained auditory function 2.5 years post-treatment, suggesting that the therapy may offer a permanent solution for those with this specific genetic mutation.